In approximately 10 to 15 percent of congenital hemophilia A patients circulating antibodies to factor VIII appear in the blood that poses a serious problem in their treatment. A number of methods and preparations are used in the clinical practice to overcome this problem. Authors report their favourable clinical experience with the administration of polyelectrolyte-fractionated porcine factor VIII. concentrate in a hemophiliac child for the first time in Hungary and a brief review of the clinical methods in use in the management of factor VIII. inhibitors.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
factor viii
16
porcine factor
8
[poly-electrolyte fractionated
4
fractionated porcine
4
factor
4
viii
4
viii treatment
4
treatment hemophilia
4
hemophilia percent
4
percent congenital
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!